Pricing Disclosures

Select state to view state-required pricing disclosures

default-sum-open-background-color
default-sum-close-background-color
false
default-sum-open-hover-color
default-sum-open-focus-color
default-sum-close-focus-color
.default-sum-close-hover-color

Colorado

Pursuant to Colorado law, C.R.S. 12-280-308, Merck is required to provide to Colorado prescribers pricing information about certain Merck products, as well as the names of generic products in the same therapeutic class. The generic products listed are not necessarily the generic form of the Merck product. Rather, these drugs could be the generic form of a non-Merck drug in the same therapeutic class. Depending on the number of generic prescription drugs in the therapeutic class, this list may not be inclusive of all. The generic products listed are not necessarily interchangeable with the Merck product, nor should they be implied to have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

The prices listed reflect Merck’s Wholesale Acquisition Costs for the Merck product. The prices paid by consumers may vary from the prices listed.

#00857C
  • BELSOMRA®

(suvorexant) 5, 10, 15, 20 mg tablets, for oral use, C-IV

#00857c
  • BRIDION®

(sugammadex) injection 100 mg/mL (equivalent to 108.8 mg/mL sugammadex sodium), for intravenous use

#00857C
  • DELSTRIGO®

(doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg) tablets

Before prescribing DELSTRIGO, please read the accompanying Prescribing Information, including the Boxed Warning about posttreatment acute exacerbation of Hepatitis B.

#00857c
  • DIFICID®

(fidaxomicin) tablets 200 mg | oral suspension 200 mg/5 ml

#00857c
  • ISENTRESS® & ISENTRESS® HD

ISENTRESS® (raltegravir 400 mg) film-coated tablets, for oral use; chewable tablets, for oral use; oral suspension and ISENTRESS® HD (raltegravir 600 mg) film-coated tablets, for oral use

#00857c
  • JANUMET® & JANUMET® XR

JANUMET® (sitagliptin and metformin HCI) 50/500 mg, 50/1000 mg tablets and JANUMET® XR (sitagliptin and metformin HCI extended-release) 50/500 mg, 50/1000 mg, 100/1000 mg tablets

Before prescribing JANUMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.

 

Before prescribing JANUMET XR, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.

#00857c
  • JANUVIA®

(sitagliptin) 25 mg, 50 mg, 100 mg tablets

#00857C
  • KEYTRUDA®

(pembrolizumab) injection 100 mg

#00857C
  • LAGEVRIO™

(molnupiravir) 200 mg capsules

#00857C
  • M-M-R®II

(Measles, Mumps, and Rubella Virus Vaccine Live)

#00857C
  • PIFELTRO®

(doravirine 100 mg) tablets

#00857C
  • PNEUMOVAX®23

(Pneumococcal Vaccine Polyvalent)

#00857c
  • PREVYMIS®

(letermovir) 240 mg, 480 mg tablets; Injection 20 mg/mL

#00857C
  • ProQuad®

(Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

#00857c
  • RECARBRIO™

(imipenem, cilastatin, and relebactam) for injection 1.25 g

#00857C
  • RECOMBIVAX HB®

[Hepatitis B Vaccine (Recombinant)]

#00857C
  • RotaTeq®

(Rotavirus Vaccine, Live, Oral, Pentavalent)

#00857C
  • SEGLUROMET®

(ertugliflozin and metformin HCI) 2.5 mg/500 mg, 2.5 mg/1000 mg, 7.5 mg/500 mg, 7.5 mg/1000 mg tablets

Before prescribing SEGLUROMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.

#00857c
  • SIVEXTRO®

(tedizolid phosphate) 200 mg injection, for intravenous use; 200 mg tablet, for oral use

#00857c
  • STEGLATRO®

(ertugliflozin) 5 mg, 15 mg tablets

#00857c
  • STEGLUJAN®

(ertugliflozin and sitagliptin) 5 mg/100 mg, 15 mg/100 mg tablets

#00857C
  • VAQTA®

(Hepatitis A Vaccine, Inactivated)

#00857C
  • VARIVAX®

(Varicella Virus Vaccine Live)

#00857C
  • VAXNEUVANCE™

(Pneumococcal 15-valent Conjugate Vaccine)

#00857c
  • VERQUVO®

(vericiguat) tablets 2.5 mg, 5 mg, 10 mg

Before prescribing VERQUVO, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.

#00857c
  • WELIREG™

(belzutifan) 40 mg tablets

Before prescribing WELIREG, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.

#00857c
  • ZERBAXA®

(ceftolozane and tazobactam) for injection (1.5 g), for intravenous use

Alliance Products*

#00857C
  • LENVIMA®**

(lenvatinib) capsules, 10 mg & 4 mg

#00857C
  • LYNPARZA®***

(olaparib) tablets, 150 mg

*These products are co-developed and co-commercialized with another manufacturer.

**LENVIMA® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.

***LYNPARZA® is a registered trademark of the AstraZeneca group of companies.

default-sum-open-background-color
default-sum-close-background-color
false
default-sum-open-hover-color
default-sum-open-focus-color
default-sum-close-focus-color
.default-sum-close-hover-color

Connecticut

Pursuant to Connecticut law, Pub. Act 23-171, Sec. 5, Merck is required under certain circumstances to provide pricing and other information about Merck products to Connecticut prescribers and pharmacists. The prices listed reflect Merck’s Wholesale Acquisition Costs for the Merck product. As explained within, the prices paid by consumers may vary from the prices listed.

#00857C
  • BELSOMRA®

(suvorexant) 5, 10, 15, 20 mg tablets, for oral use, C-IV

#00857c
  • BRIDION®

(sugammadex) injection 100 mg/mL (equivalent to 108.8 mg/mL sugammadex sodium), for intravenous use

#00857C
  • DELSTRIGO®

(doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg) tablets

Before prescribing DELSTRIGO, please read the accompanying Prescribing Information, including the Boxed Warning about posttreatment acute exacerbation of Hepatitis B.

#00857c
  • DIFICID®

(fidaxomicin) tablets 200 mg | oral suspension 200 mg/5 ml

#00857c
  • ISENTRESS® & ISENTRESS® HD

ISENTRESS® (raltegravir 400 mg) film-coated tablets, for oral use; chewable tablets, for oral use; oral suspension and ISENTRESS® HD (raltegravir 600 mg) film-coated tablets, for oral use

#00857c
  • JANUMET® & JANUMET® XR

JANUMET® (sitagliptin and metformin HCI) 50/500 mg, 50/1000 mg tablets and JANUMET® XR (sitagliptin and metformin HCI extended-release) 50/500 mg, 50/1000 mg, 100/1000 mg tablets

Before prescribing JANUMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.

 

Before prescribing JANUMET XR, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.

#00857c
  • JANUVIA®

(sitagliptin) 25 mg, 50 mg, 100 mg tablets

#00857C
  • KEYTRUDA®

(pembrolizumab) injection 100 mg

#00857C
  • LAGEVRIO™

(molnupiravir) 200 mg capsules

#00857C
  • M-M-R®II

(Measles, Mumps, and Rubella Virus Vaccine Live)

#00857C
  • PIFELTRO®

(doravirine 100 mg) tablets

#00857C
  • PNEUMOVAX®23

(Pneumococcal Vaccine Polyvalent)

#00857c
  • PREVYMIS®

(letermovir) 240 mg, 480 mg tablets; Injection 20 mg/mL

#00857C
  • ProQuad®

(Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

#00857c
  • RECARBRIO™

(imipenem, cilastatin, and relebactam) for injection 1.25 g

#00857C
  • RECOMBIVAX HB®

[Hepatitis B Vaccine (Recombinant)]

#00857C
  • RotaTeq®

(Rotavirus Vaccine, Live, Oral, Pentavalent)

#00857C
  • SEGLUROMET®

(ertugliflozin and metformin HCI) 2.5 mg/500 mg, 2.5 mg/1000 mg, 7.5 mg/500 mg, 7.5 mg/1000 mg tablets

Before prescribing SEGLUROMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.

#00857c
  • SIVEXTRO®

(tedizolid phosphate) 200 mg injection, for intravenous use; 200 mg tablet, for oral use

#00857c
  • STEGLATRO®

(ertugliflozin) 5 mg, 15 mg tablets

#00857c
  • STEGLUJAN®

(ertugliflozin and sitagliptin) 5 mg/100 mg, 15 mg/100 mg tablets

#00857C
  • VAQTA®

(Hepatitis A Vaccine, Inactivated)

#00857C
  • VARIVAX®

(Varicella Virus Vaccine Live)

#00857C
  • VAXNEUVANCE™

(Pneumococcal 15-valent Conjugate Vaccine)

#00857c
  • VERQUVO®

(vericiguat) tablets 2.5 mg, 5 mg, 10 mg

Before prescribing VERQUVO, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.

#00857c
  • WELIREG™

(belzutifan) 40 mg tablets

Before prescribing WELIREG, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.

#00857c
  • ZERBAXA®

(ceftolozane and tazobactam) for injection (1.5 g), for intravenous use

Alliance Products*

#00857C
  • LENVIMA®**

(lenvatinib) capsules, 10 mg & 4 mg

#00857C
  • LYNPARZA®***

(olaparib) tablets, 150 mg

*These products are co-developed and co-commercialized with another manufacturer.

**LENVIMA® is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.

***LYNPARZA® is a registered trademark of the AstraZeneca group of companies.

default-sum-open-background-color
default-sum-close-background-color
false
default-sum-open-hover-color
default-sum-open-focus-color
default-sum-close-focus-color
.default-sum-close-hover-color

Vermont

Pursuant to Vermont’s Pharmaceutical Marketer Price Disclosure Law, 18 V.S.A. § 4633, Merck is required to provide to Vermont prescribers pricing information about certain Merck products, as well as other products in the same therapeutic class. The “other products” listed are not necessarily interchangeable with the Merck product, nor should they be implied to have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

Further, as required by Vermont law, the prices listed are derived from Average Wholesale Price, which is provided by a third party publisher. The prices paid by consumers may vary from the prices listed.

#00857C
  • BELSOMRA®

(suvorexant) 5, 10, 15, 20 mg tablets, for oral use, C-IV

#00857C
  • DELSTRIGO®

(doravirine 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg) tablets

Before prescribing DELSTRIGO, please read the accompanying Prescribing Information, including the Boxed Warning about posttreatment acute exacerbation of Hepatitis B.

#00857c
  • DIFICID®

(fidaxomicin) tablets 200 mg | oral suspension 200 mg/5 ml

#00857c
  • ISENTRESS® & ISENTRESS® HD

ISENTRESS® (raltegravir 400 mg) film-coated tablets, for oral use; chewable tablets, for oral use; oral suspension and ISENTRESS® HD (raltegravir 600 mg) film-coated tablets, for oral use

#00857c
  • JANUMET® & JANUMET® XR

JANUMET® (sitagliptin and metformin HCI) 50/500 mg, 50/1000 mg tablets and JANUMET® XR (sitagliptin and metformin HCI extended-release) 50/500 mg, 50/1000 mg, 100/1000 mg tablets

Before prescribing JANUMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.

 

Before prescribing JANUMET XR, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.

#00857c
  • JANUVIA®

(sitagliptin) 25 mg, 50 mg, 100 mg tablets

#00857C
  • LAGEVRIO™

(molnupiravir) 200 mg capsules

#00857C
  • PIFELTRO®

(doravirine 100 mg) tablets

#00857c
  • PREVYMIS®

(letermovir) 240 mg, 480 mg tablets; Injection 20 mg/mL

#00857C
  • SEGLUROMET®

(ertugliflozin and metformin HCI) 2.5 mg/500 mg, 2.5 mg/1000 mg, 7.5 mg/500 mg, 7.5 mg/1000 mg tablets

Before prescribing SEGLUROMET, please read the Prescribing Information, including the Boxed Warning about lactic acidosis.

#00857c
  • SIVEXTRO®

(tedizolid phosphate) 200 mg injection, for intravenous use; 200 mg tablet, for oral use

#00857c
  • STEGLATRO®

(ertugliflozin) 5 mg, 15 mg tablets

#00857c
  • STEGLUJAN®

(ertugliflozin and sitagliptin) 5 mg/100 mg, 15 mg/100 mg tablets

#00857c
  • VERQUVO®

(vericiguat) tablets 2.5 mg, 5 mg, 10 mg

Before prescribing VERQUVO, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.

#00857c
  • WELIREG™

(belzutifan) 40 mg tablets

Before prescribing WELIREG, please read the Prescribing Information, including the Boxed Warning about embryo-fetal toxicity.

Alliance Products*